ZH3D7 somatic hybrid cell line panel

These cell lines are a powerful tool for studying the molecular and cellular mechanisms of breast tumour progression and therapy resistance.

Contributors

Institute
Erasmus University Medical Center (Erasmus MC)
SKU: 154647
Product description: Endocrine therapy of breast cancer has been applied widely and proven to be effective. However, in many instances endocrine treatments ultimately fail due to the development of an estrogen-independent therapy resistant phenotype. To elucidate the molecular mechanism underlying this endocrine therapy failure, the laboratory of Lambert Dorssers applied random insertional mutagenesis using defective retroviruses to identify the main genes conferring estrogen independence. Out of 15 candidate BCAR genes, several including BCAR1 and BCAR2 were shown to directly underlie estrogen independence. Somatic cell fusions were generated for these two genes in the hygromycin-B-resistant variant of ZR-75-1 breast cancer cells (ZH3D7) resulting in a panel of 3 cell lines (Cat No 154639-154641). These cell lines are a powerful tool for studying the molecular and cellular mechanisms of breast tumour progression and therapy resistance.
Conditional: No
Production details: Hygromycin-B-resistant variants of ZR-75-1 cells, ZH3D7, were used as recipients in the somatic-cell-fusion experiments. Donor cells were two different anti-estrogen-resistant cell lines. Approximately 6 million donor cells, which were gamma-irradiated with approx 40 Gy and 3 million recipient cells were plated in 25cm flasks in RBCS medium with estradiol. After strong adherence to the flasks in 36 to 48 hr, cells were washed 3 times in RPMI-1640 without serum and incubated with 1 ml polyethy…
Parental cell line: ZH3D7
Disease: Cancer
Cat. #: 154647
Tool sub type: Continuous
Unit size: 1×10^6 cells / vial
Cancer types: Breast cancer
Research Fields: Cancer; Drug development
Organism: Human
Tissue: Breast
Model: Cancer Model
Cancer Types In Detail: Mammary ductal carcinoma
Format: Frozen
Shipping conditions: Dry ice
Growth medium: RBCS medium containing estradiol and Geneticin (G418)
References:

Brinkman et al. 2000. J Natl Cancer Inst. 92(2):112-20. PMID: 10639512.

Dorssers et al. 1997. Int J Cancer. 72(4):700-5. PMID: 9259413.

Images

View Gallery

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.